ESTRO meets Asia 2024 - Abstract Book

S87

Interdisciplinary – Breast

ESTRO meets Asia

Keywords: Hypofractionated RT, Disease free survival

References:

1. Koulis TA, Nichol AM, Truong PT, Speers C, Gondara L, Tyldesley S, Lohrisch C, Weir L, Olson RA. Hypofractionated adjuvant radiation therapy is effective for patients with lymph node–positive breast cancer: a population-based analysis. International Journal of Radiation Oncology* Biology* Physics. 2020 Dec 1;108(5):1150 8. 2. Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS, Alhasso A, Adamson D. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. The Lancet Oncology. 2018 Nov 1;19(11):1516-29. 3. Venigalla S, Guttmann DM, Jain V, Sharma S, Freedman GM, Shabason JE. Trends and patterns of utilization of hypofractionated postmastectomy radiotherapy: a National Cancer Database analysis. Clinical breast cancer. 2018 Oct 1;18(5):e899-908.

363

Proffered Paper

COVID-19 pandemic impact on breast cancer care: A tertiary cancer center case-control study.

E Ramya 1 , Jince Mary Mathew 1 , Revathy Krishnamurthy 1 , Rima Pathak 1 , Tabassum Wadasadawala 1 , T G Vasantharaja 2 , Rajiv Sarin 1 1 Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. 2 Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India

Purpose/Objective:

The COVID-19 pandemic, lockdown restrictions, and COVID-19 adaptations on breast cancer management had a wide-ranging impact on clinical outcomes in breast cancer patients. Few studies have quantified these adverse impacts during and after the pandemic. To study this impact we established a cohort of treatment-naive newly diagnosed consecutive breast cancer cases registered at a comprehensive cancer center in Mumbai during the strict lockdown period and a pre-covid control cohort registered in the preceding year. We evaluated how the COVID-19 outbreak, lockdown, and hospital adaptations influenced clinical presentation, deviations from Standard of Care (SoC) in management, and clinical outcomes.

Material/Methods:

The hospital's electronic database was screened to identify the pandemic cohort (treatment-naive breast cancer cases registered during lockdown from 25 March - 31 October 2020) and pre-pandemic controls (treatment-naive breast cancer patients registered in the preceding year from 1 February to 30 April 2019). Standard of Care was defined as per national and institutional evidence-based guidelines. Patient demographic, stage, deviations in SoC, 3-year overall, and recurrence-free survival probability were compared between the cohorts.

Results: